IQVIA Holdings Inc. (IQV)
NYSE: IQV · Real-Time Price · USD
259.82
+3.77 (1.47%)
Aug 21, 2026, 4:00 PM EDT - Market closed
IQVIA Holdings Revenue
IQVIA Holdings had revenue of $4.37B in the quarter ending June 30, 2026, with 8.74% growth. This brings the company's revenue in the last twelve months to $16.98B, up 8.17% year-over-year. In the year 2025, IQVIA Holdings had annual revenue of $16.31B with 5.87% growth.
Revenue (ttm)
$16.98B
Revenue Growth
+8.17%
P/S Ratio
2.52
Revenue / Employee
$182,613
Employees
93,000
Market Cap
42.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.31B | 905.00M | 5.87% |
| Dec 31, 2024 | 15.41B | 421.00M | 2.81% |
| Dec 31, 2023 | 14.98B | 574.00M | 3.98% |
| Dec 31, 2022 | 14.41B | 536.00M | 3.86% |
| Dec 31, 2021 | 13.87B | 2.52B | 22.14% |
| Dec 31, 2020 | 11.36B | 271.00M | 2.44% |
| Dec 31, 2019 | 11.09B | 676.00M | 6.49% |
| Dec 31, 2018 | 10.41B | 710.00M | 7.32% |
| Dec 31, 2017 | 9.70B | 2.89B | 42.36% |
| Dec 31, 2016 | 6.82B | 1.08B | 18.79% |
| Dec 31, 2015 | 5.74B | 277.00M | 5.07% |
| Dec 31, 2014 | 5.46B | 360.46M | 7.07% |
| Dec 31, 2013 | 5.10B | 234.03M | 4.81% |
| Dec 31, 2012 | 4.87B | 537.77M | 12.43% |
| Dec 31, 2011 | 4.33B | 403.73M | 10.29% |
| Dec 31, 2010 | 3.92B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 14.35B |
| Quest Diagnostics | 11.56B |
| Agilent Technologies | 7.23B |
| Waters | 4.64B |
| IDEXX Laboratories | 4.55B |
| Illumina | 4.49B |
| Mettler-Toledo International | 4.13B |
| Charles River Laboratories International | 4.00B |
IQV News
- 3 days ago - IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year - Business Wire
- 6 days ago - IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group - Business Wire
- 19 days ago - Iqvia, Medera partner to advance cardiac gene therapy - TheFly
- 19 days ago - IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery - Business Wire
- 25 days ago - Iqvia price target raised to $247 from $221 at RBC Capital - TheFly
- 25 days ago - Iqvia price target raised to $288 from $233 at TD Cowen - TheFly
- 25 days ago - Iqvia price target raised to $280 from $245 at BofA - TheFly
- 25 days ago - Iqvia price target raised to $270 from $210 at BMO Capital - TheFly